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Background: S100A9 has been shown to be important for the function of so called Myeloid Derived Suppressor
Cells (MDSC). Cells with a similar phenotype are also involved in pro-inflammatory processes, and we therefore
wanted to investigate the gene expression and function of these cells in animals that were either subjected to
chronic inflammation, or inoculated with tumors.
Methods: CD11b+Ly6C++ and Ly6G+ cells were isolated from spleen, tumor tissue or inflammatory granulomas.
S100A9, Arginase 1 and iNOS gene expression in the various CD11b+ cell populations was analyzed using Q-PCR.
The suppressive activity of the CD11b+ cell populations from different donors was studied in co-culture
experiments.
Results: S100A9 was shown to be expressed mainly in splenic CD11b+Ly6C+G+ cells both at the RNA and protein
level. Arginase I and iNOS expression could be detected in both CD11b+Ly6C+Ly6G+ and CD11b+Ly6C+G-/C++G-
derived from tumors or a site of chronic inflammation, but was very low in the same cell populations isolated from
the spleen. CD11b+ cells isolated from mice with peritoneal chronic inflammation were able to stimulate T
lymphocytes, while CD11b+ cells from mice with peritoneal tumors suppressed T cell growth.
Conclusion: An identical CD11b+Ly6C++G- cell population appears to have the ability to adopt immune stimulatory
or immune suppressive functions dependent on the presence of a local inflammatory or tumor microenvironment.
Thus, there is a functional plasticity in the CD11b+Ly6C++G- cell population that cannot be distinguished with the
current molecular markers.
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S100A9 is a Ca++ binding protein that shows elevated
serum levels in patients with inflammatory diseases [1],
but also in some cancer patients [2]. In serum, S100A9
is mostly present as a heterodimer together with another
S100 protein, S100A8 [3]. S100A9 and S100A8 are
expressed in high amounts in neutrophils but also in im-
mature monocytes [4].
Various biological functions have been ascribed to
S100A9. Hence, S100A9 has been shown to bind to Toll
Like Receptor 4 (TLR4) and to the Receptor of Advanced
Glycation End products (RAGE) [5]. Both of these re* Correspondence: Tomas.leanderson@med.lu.se
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reproduction in any medium, provided the orceptors have been shown to be involved in inflammatory
responses, but also to promote tumor growth [6,7].
S100A9 has also been shown to be involved in the process
of tumor metastasis [8]. In a recent publication, we inves-
tigated the impact of S100A9- and TLR-4 deficiency on
tumor growth in the TRAMP prostate cancer model [9].
Our results demonstrated a significant delay of tumor
growth in these animals. We obtained similar data on
tumor growth when S100A9-deficient (S100A9−/−) and
TLR4−/− mice were transplanted with EL4 lymphoma
cells. As EL4 tumor growth was not reduced in RAGE−/−
mice, we concluded that the interaction of S100A9 with
TLR4 promotes tumor growth. This conclusion was sup-
ported by the finding that ABR-215050, a small moleculel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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inhibited EL4 tumor growth [9].
Interestingly, S100A9 has also been shown to be im-
portant for the function of so called Myeloid Derived
Suppressor Cells (MDSC) [10]. These cells consist of a
heterogeneous population of myeloid cells that is usually
described as being CD11b+ and GR1+ cells [11]. The
GR1 marker is a composite epitope between the Ly6C
and Ly6G antigens, and MDSC can be further subdivided
into Ly6C++ monocytic and Ly6G+ granulocytic MDSCs
using these two antigens [10]. The MDSC population pro-
motes tumor growth by several different mechanisms,
amongst these by expressing the arginine metabolizing en-
zyme Arginase I (Arg I) and inducible nitric oxide syn-
thase (iNOS) [11-13]. Expression of these enzymes
provides strong immunosuppression by inhibiting T cell
activity and thus the adaptive immune response towards
the tumor. CD11b+Ly6C++ and Ly6G+ cells are also
involved in pro-inflammatory processes and we therefore
wanted to investigate the gene expression and function of
these cells in animals that were either subjected to chronic
inflammation, or inoculated with tumors.
We show in this communication that although isolated
CD11b+ subpopulations cannot be distinguished by their
expression of S100A9, Arg I or iNOS in the two settings,
they are stimulatory to T cells when isolated from spleens
of mice with chronic inflammation while being immune
suppressive when isolated from mice with tumors. Thus,
there is a functional plasticity in the CD11b+Gr1+ popula-




All animal experiments have been approved by a local
ethics committee (“Malmö/Lunds Djurförsöksetiska
nämnd”; DNR M 275–08 and M 60–10). C57BL/6 mice,
(Taconic M&B, Ry, Denmark) mice were kept in an SPF
animal facility at BMC, Lund. Twelve weeks old animals
were injected subcutaneously with 50,000 EL4 lymph-
oma cells in 100 μl PBS. As control, 100 μl PBS alone
was injected. After 14 days the animals were scored for
tumor growth by palpation. Spleens and tumors were
dissected, the cell suspension was thereafter passed
through a 70 μm cell strainer and cells washed in Hank’s
BSS (Invitrogen Life Technologies, Paisley, UK). When
indicated 20,000 EL-4 cells were injected IP and after
10 days peritoneal cavity lavage were used as source for
CD11b+ cells.
TMPD model
All TMPD animal experiments were conducted in the
animal facility at Active Biotech AB. Eight to nine weeks
old female BALB/c mice (Taconic, Denmark) were givena single intraperitoneal injection (0.5 ml) of 2,6,10,14-
Tetramethyl-Pentadecane (TMPD, pristane; Sigma-Aldrich,
US). Two weeks after TMPD administration the spleen,
peritoneal cells and granulomas were harvested. The spleen
was mashed through a 70 μm cell strainer. The peritoneal
cavity was lavaged with 5 ml PBS and cells were collected
by centrifugation. The granulomas were picked from the
peritoneal lining and mashed through a 70 μm cell strainer.
All cell samples were re-suspended in RPMI 1640 supple-
mented with 10% FCS.
Cell culture conditions
CD11b+ cells were enriched from C57Bl/6 or BALB/c
spleens with magnetic cell sorting (MACS; Miltenyi Biotec,
Bergisch Gladbach, Germany), performed according to the
manufacturer’s protocol, using anti-CD11b magnetic beads
(Miltenyi). The cells were separated on mini MACS
columns (Miltenyi) and yielded approximately 90% pure
cells. Splenic CD4 and CD11c positive cells were enriched
in the same way using anti-CD4 or anti-CD11c antibody-
conjugated beads.
Suppressor cell activity was assessed by co-culturing vari-
ous numbers of CD11b+ cells with 5 × 104 CD4+ cells and
3 × 103 CD11c+ cells in 200 μl cultures in round-bottom
96-well plates (Costar, Cambridge, MA). T cells were poly-
clonally stimulated by the addition of 1 μg/ml anti-CD3
antibodies (145.2C11) and 1 μg/ml anti-CD28 to the cul-
tures. Cells were cultured in RPMI medium (Gibco) sup-
plemented with 50 μM 2-ME, antibiotics, 10% FCS, 1 mM
sodium pyruvate and 10 mM Hepes buffer (all supple-
ments from Gibco) at 37°C, 5% CO2. Thymidine incorpor-
ation was measured on day 3 of culture after a 4-h pulse
with 1 μCi [3H] thymidine (Amersham, Life Science).
Q-PCR
Splenic CD11b+ cells were purified using anti-CD11b mag-
netic beads and LS-columns (Miltenyi Biotech, Bergisch
Gladbach, Germany), as described above. Total RNA was
extracted from CD11b+ cell preparations by use of the
Purelink RNA mini Kit (Invitrogen). RNA was reverse
transcribed to cDNA by use of the SuperScript III Plat-
inum synthesis system (Invitrogen). Real-time PCR (RT-
PCR) was performed for the detection of S100A9, Arginase
and iNOS RNA and quantified using a SYBR GreenER kit
(Invitrogen) in a MYIQ (Bio-Rad) PCR machine. The
threshold cycle number was determined and relative ex-
pression level of each mRNA was determined using the
formula 2(Rt– Et), where Rt and Et are the threshold cycles
for the reference gene (β-actin) and the target gene,
respectively.
Flow cytometry
Flow cytometric analysis was performed on spleen cell
suspensions, as indicated. Primary antibodies used were:
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Pharmingen) and Ly6C-biotin (BD Pharmingen). Bioti-
nylated antibodies were detected with streptavidin-
QD605 (Invitrogen). Data were acquired using a FACS
LSR II flow cytometer (BD Biosciences) and analyzed
using FlowJo software (Tree Star).
Immunohistochemistry
Tissues analyzed with immunohistology were embedded
in OCT compound (Tissue-TekW), and snap-frozen in
liquid nitrogen. Cryosections (5–6 μm) were prepared
on microscope slides, air dried and frozen at −20°C until
staining procedures. Paraformaldehyde fixed sections
were incubated with blocking 1% BSA 10% serum and
FcRII/III blocker solution followed by Avidin/Biotin
Blocking kit (Vector Laboratories, Inc. Burlingame, CA,
USA). Thereafter the sections were incubated for 30 min
at room temperature with primary antibodies: Rabbit-
anti-murine S100A9, or the appropriate isotype controls
(BD Pharmingen), followed by Donkey- anti- rabbit-
Alexa488 (Molecular Probes) and anti-mouse CD11b-
APC conjugate (eBioscience San Diego CA, USA),
Ly6G-PE (BD Pharmingen), Ly6C-biotin (BD Pharmin-
gen) followed by Streptavedin labeled with Alexa-647
(BD Pharmingen). The slides were mounted using Pro-
Long Gold mounting media (Invitrogen, Oregon, USA)
and inspected in a Zeiss microscope and analyzed with
Volocity software.
Western blot
Spleen cells were stained as described above and Ly6C+G+,
Ly6C+G- and Ly6C++G- subpopulations were sorted
using a FACSAria flow cytometer (BD Biosciences). For
Western blot, 10 μg of proteins was loaded onto 12%
polyacrylamide gels (C.B.S. Scientific, San Diego, CA,
USA). Proteins were subsequently transferred to PVDF
membrane (Roche), which was saturated with 1% dry
milk in PBS. Thereafter, the membranes were incubated
with Rat anti-Mouse S100A9 and Rat anti-Actin (RnD
Systems) as primary antibody and Rabbit anti-Rat –HRP
(SouthernBiotec Birmingham, Alabama, USA) as second-
ary antibodies and filters developed using ECL kit (GE
Healthcare, UK).
Results
S100A9 expression in splenic CD11b+ cells
S100A9 has been shown to be involved in the function
and accumulation of MDSC [10] and we first wanted to
analyze the expression of S100A9 in various subsets of
CD11b+ cells from the spleen of normal C57BL/6 mice
in order to define whether there was a selective expres-
sion in a defined cell subset. To this end, we sorted
CD11b+ cells using FACS with regard to the expression
of the Ly6G and Ly6C markers into three populations;Ly6C+G+, Ly6C+G- and Ly6C++G-, as shown in Figure 1A.
RNA was prepared from the isolated cell populations and
S100A9 expression was measured using Q-PCR. As
shown in Figure 1B, the Ly6C+G+ population appeared to
be the main S100A9 expressing subpopulation within the
CD11b+ compartment. This was confirmed at the protein
level using Western blotting (Figure 1C). Furthermore,
when CD11b+ cells were stained and analyzed using
immunohistochemistry, the majority of the S100A9+ cells
also stained brightly for Ly6G while Ly6C+ cells only
stained weakly, if at all, with anti-S100A9 (Figure 1D).
Thus, S100A9 is differentially expressed within the CD11b
+Gr1+ cell compartment where the Ly6C+G+ cells is the
main S100A9 expressing cell population.
Effect of tumor on CD11b+ cell populations and S100A9
We next analyzed the effect of a tumor challenge on the
CD11b+ cell populations and their respective S100A9 ex-
pression. C57BL/6 mice were inoculated with EL4
lymphoma cells subcutaneously and 14 days after the in-
oculum the splenic CD11b+ cells were analyzed by
FACS, as above. As shown in Figure 2A, the percentage
of CD11b+Ly6C+G+ increased while CD11b+Ly6C+G-
cells in the spleen decreased in tumor bearing animals.
The composition of the CD11b+ cells in the spleen and
in tumor tissue differed. Hence, the CD11b+Ly6C+G+
population was reduced in the tumor while the CD11b+
Ly6C+G- population was overrepresented (Figure 2B).
The CD11b+Ly6C++G- population was also slightly ele-
vated in the EL-4 tumors.
We next wanted to investigate the effect of tumor inocu-
lation on S100A9 expression (Figure 2C). In order to get
enough cells from tumor tissue to be able to extract suffi-
cient amount of RNA for analysis, we pooled the CD11b+
Ly6C+G- and CD11b+Ly6C++G- populations. There was a
modest increase of S100A9 mRNA in both splenic popu-
lations (CD11b+Ly6C+G+ and CD11b+Ly6C+G-/C++G-)
in EL-4 tumor bearing animals. However, when cells with
the same surface phenotype were isolated from the
tumor tissue, the S100A9 RNA expression was lower
compared to the corresponding splenic cell populations.
Using Western blot (Figure 2D) the down-regulation of
S100A9 could also be seen in tumor-derived CD11b
+Ly6C+G+ cells at the protein level, although not as
marked as at the RNA level. We conclude from these
experiments that the distribution of CD11b+ cell subpo-
pulations, as well as their S100A9 expression, appears to
be dynamic and change both depending on tumor chal-
lenge and on tissue location.
Differential S100A9 expression during chronic
inflammation
Having investigated the effect of a tumor challenge on the



































































































Figure 1 Expression of S100A9 in the splenic CD11b+ cells. A. Dot-plots from FACS analysis to illustrate the gating to obtain the different
CD11b+ subpopulations. B. RT-PCR analysis of S100A9 RNA expression in FACS sorted cells from spleen, as indicated. C. Western blot analysis of
S100A9 expression on FACS sorted cell populations from spleen. D. Cytospin of splenic CD11b sorted cells were stained with anti-Ly6G in red,
anti-Ly6C in purple, anti-S100A9 in green and Hoecst in blue.














































































































































Figure 2 Tumor microenvironment induces a shift in CD11b+ cell populations. A. Proportion of splenic CD11b+ cell population in C57BL/6
control animals and animals inoculated 14 days earlier with EL-4 lymphoma cells. B. Proportion of different CD11b+ cell populations in spleen
and tumor from EL-4 inoculated C57BL/6 mice. C. RT-PCR analysis of S100A9 RNA expression in sorted cells from spleen and EL-4 tumors, as
indicated. The threshold cycle number was determined and relative expression compared to the reference gene (β-actin) and the target gene,
respectively. D. Western blot analysis of S100A9 expression on sorted cell populations from spleen and EL-4 tumors, as indicated. The Gray Value
(Median) from Adobe Photoshop were used to determined the level of S100A9 and the reference gene (β-actin) expression. Statistical analysis
was performed using Student’s t-test (*p < 0.05; **p < 0.01;***p < 0.001).
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inflammation. To this end we used a mouse model where
injection of TMPD (pristane) into the peritoneum induces
granuloma formation, ultimately resulting in a SLE-like
disease [14]. The mice were sacrificed 14 days after TMPD
injection and the CD11b+ cells from the spleens and
granulomas were analyzed using FACS and Q-PCR. We first
investigated the effect on the CD11b+ cell populations in the
spleen in BALB/c control animals and TMPD injected ani-
mals. Here, the CD11b+Ly6C+G+ cell population increased,
while the CD11b+Ly6C++G- population decreased upon
TMPD injection (Figure 3A). Furthermore, the CD11b+
population was analyzed also in granulomas with respect to
the expression of the Ly6C and Ly6G markers. The Ly6C+G+population was reduced in granulomas compared to
spleen, the Ly6C+G- population similar, while the Ly6C++G-
population was elevated in granulomas (Figure 3B).
Thus, with regard to these markers, different subpo-
pulations of CD11b+ cells appear to accumulate at the site
of TMPD-induced chronic inflammation as compared to
tumor tissue.
We also analyzed the S100A9 expression in the differ-
ent CD11b+ subpopulations using Q-PCR (Figure 3C).
In the spleen, the most pronounced S100A9 expression
was in the Ly6C+G+ population, similarly as to what was
observed in tumor bearing animals. Also, the S100A9
expression in this cell population was down-regulated in














































































































Figure 3 Chronic inflammatory microenvironment induces a shift of CD11b+ cell populations. A. Proportion of splenic CD11b+ cell
population in BALB/c control animals and animals inoculated 14 days earlier with pristane i.p.. B. Proportion of different CD11b+ cell populations
in spleen and granuloma inoculated 14 days earlier with pristane i.p.. C. RT-PCR analysis of S100A9 RNA expression in sorted cells from spleen and
granulomas from animals inoculated 14 days earlier with pristane i.p., as indicated. The threshold cycle number was determined and relative
expression compared to the reference gene (β-actin) and the target gene, respectively. Statistical analysis was performed using Student’s t-test
(*p < 0.05; **p < 0.01;***p < 0.001).
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tumors or inflamed tissue
We next wanted to gain some insight into the functional
properties of the CD11b+ subpopulations under different
conditions. Firstly, we analyzed arginase-I (Arg) and
iNOS RNA expression from the CD11b+ subpopulations
using RT-PCR. As shown in Figure 4A-C, very low Arg
expression was detected in both CD11b+ Ly6C+G+ and
Ly6C+G-/C++G- cells isolated from the spleen of either con-






















































































































Figure 4 Arginase and iNOS expression are very similar in CD11b+ ce
microenvironments. Indicated CD11b+ cell populations were isolated by
and tumor tissue of mice carrying EL4 tumor (B,E) or from spleen and gran
isolated from the sorted cells and qRT-PCR was performed to determine ex
indicated. qRT-PCR was performed in triplicate and data displayed as mean
A-C and D-F.However, significant Arg expression was readily detected
in the same cell populations isolated from either tumor
tissue or granulomas. With regard to iNOS expres-
sion, a similar picture emerged (Figure 4D-F); both
Ly6C+G+ and Ly6C+G-/C++G- cells from tumors and
granulomas expressed iNOS RNA. The highest expression
was seen in the Ly6C+G+ population in both cases. Also,
no iNOS expression was detected in spleen cells from
control animals while a low expression could be detected



































































































ll subpopulations from tumors or chronic inflammatory
cell sorting from spleen of control naïve mice (A, D), or from spleen
uloma tissue of mice carrying peritoneal granulomas (C,F). RNA was
pression of Arginase I (Arg) or iNOS relative to β-actin expression, as
expression +/− SD. The same mRNA preparations were analyzed in
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clude from these experiments that the expression of the
immune regulatory molecules Arg and iNOS appears to
be up-regulated in a similar way in peripheral tissue,
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Figure 5 Effect of CD11b+ cell populations on T cell proliferation in v
exudate cells (PEC) of normal control or EL-4 carrying C57BL/6 mice were co-
proliferation induced with anti-CD3 and anti-CD28 antibodies. T cell proliferat
B. CD11b+ cells sorted from peritoneal exudate cells (PEC) of normal control o
cells and CD11c+ cells isolated form BALB/c mice and proliferation determine
proliferation (in the absence of added CD11b+ cells). C. CD11b+ cell subpop
inoculated C57BL/6 mice were co-cultured with splenic CD4+ T cells and CD
from spleens of TMPD granuloma-carrying BALB/c mice were co-cultured w
C. Proliferation in control cultures without added CD11b+ cells were analyse
mean +/− SD of triplicate cultures. Statistical analysis was performed using
and Student t-test (*p < 0.05; **p < 0.01; ***p < 0.001) in panels C and D.To further address the functionality of the CD11b+
cells in various conditions we performed co-culture
experiments with splenic CD4+ T cells stimulated with
anti-CD3 and anti-CD28 antibodies in the presence of
CD11c+ dendritic cells, as previously described [10]. The
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itro. A. Indicated numbers of CD11b+ cells sorted from the peritoneal
cultured for 3 days with splenic CD4+ T cells and CD11c+ cells and
ion was determined as described in Materials and Methods.
r granuloma-carrying BALB/c mice were co-cultured with splenic CD4+ T
d as in A. Dashed red lines in A and B indicate unsuppressed T cell
ulations (5x104/culture), as indicated, sorted from spleens of EL-4 tumor
11c+ cells as in A. D. CD11b+ cell subpopulations, as indicated, sorted
ith CD4+ T cells and CD11c+ cells isolated BALB/c mice, as described in
d in parallel. The data shows
two-way ANOVA (** p < 0.01; *** p < 0.001) in panels A and B,
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days by 3H-thymidine uptake. We first isolated CD11b+
cells from peritoneal lavage (PEC) from animals with
induced granulomas, or from animals inoculated with
EL-4 tumors intra-peritoneally, and used them in T cell
proliferation assays. As shown in Figure 5A, peritoneal
CD11b+ cells from EL-4 tumor inoculated animals were
highly immune suppressive compared to CD11b+ cells
isolated from control animals that suppressed to a lesser
extent. Peritoneal CD11b+ cells from animals with granu-
lomas, on the other hand displayed even less suppression
than control cells from normal mice (Figure 5B). Hence, a
functional distinction between CD11b+ cells isolated from
animals with EL-4 tumors or TMPD-induced chronic in-
flammation could be detected with regard to their ability
to influence T cell proliferation.
We then wanted to study the ability of splenic CD11b+
cellular subsets to suppress T cell proliferation. As
shown in Figure 5C, using FACS-separated splenic
CD11b+ cells from EL-4 tumor inoculated animals, some
immune suppressive activity was observed when adding
CD11b+Ly6C+G+ cells, as compared to the control cul-
tures where no CD11b+ cells were added. The suppres-
sive effect was even more pronounced when CD11b
+Ly6C++G- cells were added to the cultures. In contrast,
when CD11b+Ly6C++G- cells were FACS-sorted from
the spleen of animals with chronic inflammation, these
cells were immune stimulatory (Figure 5D), while
CD11b+Ly6C+G+ cells did not influence the in vitro T
cell proliferation in this assay.Discussion
In this paper we investigated the function and gene ex-
pression pattern of various CD11b+ cellular subsets. We
found that although expressing the same surface pheno-
type these cell populations were functionally different,
with respect to their capacity to influence T cell prolif-
eration, when they were isolated from tumor bearing
animals compared to animals with chronic inflamma-
tion. However, the gene expression profile of both the
Ly6C+G+ and Ly6C+G-/Ly6C++G- CD11b+ cells was sur-
prisingly similar between the two disease models. It has
been shown that CD11b+Ly6C++G- cells, which repre-
sent inflammatory monocytes, can be recruited both to
tumor sites [15] and to sites of chronic inflammation
[16,17]. Previously published data have indicated that
monocytic MDSCs (CD11b+Ly6C++Ly6G-) suppress T
cell proliferation through an iNOS dependent, Stat-1
dependent mechanism [18,19]. In the present study we
saw no correlation between iNOS mRNA content and
suppressive function of the splenic CD11b+Ly6C++Ly6G-
cells. We speculate that iNOS activity of cells derived
from tumor-bearing mice may be boosted by T cell-produced IFNγ both in vivo and in vitro [20,21], which
might explain this discrepancy.
The CD11b+Ly6C++Ly6G- population had expanded
extensively in the spleen of granuloma-carrying mice. In
contrast, mainly the CD11b+Ly6C+G+ population, and
to a lower extent the CD11b+Ly6C++Ly6G- population,
expanded in spleen of mice with experimental autoimmune
encephalomyelitis (EAE) [22]. The myeloid cells expanding
during this chronic inflammatory condition could be
regarded as MDSCs [11], since they potently suppressed T
cell proliferation [22]. The CD11b+ population expanded
during the chronic inflammation in granuloma carrying
mice analyzed in this study, could in analogy also be
regarded as MDSCs. While MDSCs expand both during
chronic and acute inflammatory conditions, it has been
proposed that suppression of adaptive immunity may not
be the only functional role of these cells (reviewed in [23]).
For example, it has recently been shown that they pro-
moted the induction of TH17 cells in EAE [24]. However,
irrespective of whether the myeloid cells in granuloma car-
rying mice do represent bona fide MDSCs, or not, the ob-
servation that the monocyte-like CD11b+Ly6C++Ly6G- cells
isolated from these mice promote, rather than suppress, T
cell proliferation further underscores the functional plasti-
city of this cell population. Nevertheless, as previously
observed in several different tumor models [11-13], we also
found that CD11b+ cells isolated from tumors are pro-
foundly immunosuppressive. Given the design of our assay,
we assume that MDSCs suppressed T cells in a contact-
dependent manner.
During the preparation of this manuscript Yi et al.
published that classical MDSCs aggrevated experimental
autoimmune encephalomyelitis (EAE) in mice [24]. This
finding is in agreement with the data presented herein;
namely that defined cell populations that have been
described as immune suppressive in one disease setting
(cancer) can have a different function in another (auto-
immunity). With regard to the clinical implications these
findings could open up for new treatments strategies.
For example, gemcitabine, originally developed as a cyto-
toxic cancer treatment, has been shown to selectively de-
plete MDSCs [25]. Our observation, and that of Yi et al.
[24], might indicate that gemcitabine also could be a
treatment option for patients with aggressive, auto-
immune/inflammatory disease.
Conclusion
We show here that when the main immune regulatory
population (CD11b+Ly6C++G-) in spleen was investi-
gated for its ability to influence T cell growth, a marked
difference was observed as cells from animals with
chronic inflammation were stimulatory, while those from
tumor bearing animals were immunosuppressive. Hence,
the same cell population appears to have the ability to
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function dependent on the presence of a local inflamma-
tory or tumor microenvironment, despite their common
origin and phenotypic similarities.
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